Bio-Techne Corporation (NASDAQ: TECH) today announced that it prevailed on another claim that Miltenyi Biotec B.V. & Co. KG commercialized antibodies developed based on information obtained by reverse ...

The Brooklyn organization, seeking new audiences and pushing boundaries, debuts Techne, four digital installations from the ...

Bio-Techne Corp. (TECH), a life sciences company, announced Tuesday that it has won a second claim of reverse engineering by Miltenyi ...

Bio-Techne (TECH) prevailed on another claim that Miltenyi Biotec KG commercialized antibodies developed based on information obtained by ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

Genomics is becoming the future of medicine as technological advancements continue to unlock our DNA’s vast potential. Given ...

明尼阿波利斯 - Bio-Techne Corporation (NASDAQ: TECH) 再次在与Miltenyi Biotec的法律纠纷中取得胜利，科隆地区法院裁定支持这家生命科学公司。法院认定Miltenyi Biotec非法销售从Bio-Techne专有的R&D Systems品牌NKG2C/CD159c抗体反向工程而来的抗体。

This was the stock's fourth consecutive day of losses.

View original content to download multimedia:https://www.prnewswire.com/news-releases/bio-techne-to-present-at-the-43rd-annual-jp-morgan-healthcare-conference ...

TECH enters a co-marketing and co-promotion agreement with Waters Corporation to expand the reach of advanced biotherapeutic ...

Shares of Bio-Techne Co. (NASDAQ:TECH – Get Free Report) have received a consensus recommendation of “Moderate Buy” from the eight ratings firms that are covering the stock, Marketbeat.com reports.